The pathogenesis of hepatocellular carcinoma

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 545-553

  Kirstein, Martha M ^a   Vogel, Arndt ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic liver disease; Gene signature; Hepatocarcinogenesis; Mutations; Non alcoholicfatty liver disease

Indexed keywords

PROTEIN P53; TOXIN; WNT PROTEIN; ADIPOCYTOKINE; AFLATOXIN; ALCOHOL; AMINOTRANSFERASE; ARID1A PROTEIN; AXIN1 PROTEIN; BETA CATENIN; CTNNB1 PROTEIN; CYTOCHROME P450 2E1; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; EXOME; GENE MUTATION; GENE STRUCTURE; GENOME ANALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LONG TERM EXPOSURE; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; AGE; ALCOHOL CONSUMPTION; APOPTOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS PARASITICUS; CANCER RISK; CANCER SURVIVAL; COFFEE; CONFERENCE PAPER; COPY NUMBER VARIATION; CYTOKINE PRODUCTION; DELTA AGENT HEPATITIS; DIABETES MELLITUS; FAMILY HISTORY; GENDER; GENE DELETION; GENE INACTIVATION; GENE OVEREXPRESSION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS C; HEREDITARY TYROSINAEMIA TYPE 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CIRRHOSIS; MEMBRANE DEPOLARIZATION; MIGRATION; MIXED INFECTION; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SURVIVAL PREDICTION; TOBACCO CONSUMPTION; TYROSINEMIA; UPREGULATION; VIREMIA; WNT SIGNALING PATHWAY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; GENETICS; HOST PATHOGEN INTERACTION; LIVER NEOPLASMS; MUTATION; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; MUTATION;

EID: 84904651915     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360499     Document Type: Article

References (78)

1. El-Serag HB: Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
3. Baffy G, Brunt EM, Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391.
4. Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
5. Han ZG: Functional genomic studies: insights into the pathogenesis of liver cancer. Annu Rev Genomics Hum Genet 2012; 13: 171-205.
6. Chang MH, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med1997; 336: 1855-1859.
7. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
8. Chen CJ, et al: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
9. Yu MW, et al: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-272.
10. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1.
11. Szpacowski J-L, Tucker L-Y: Causes of death in patients with hepatitis B: a natural history cohort study in the United States. Hepatology 2013; 58: 21-30.
12. Hosaka T, Suzuki F, Kobayashi N, Seko Y, Kawamura Y, Sezaki H, Akuta N, et al: Longterm entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
13. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, et al: The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
14. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, et al: Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
15. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, et al: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331.
16. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, et al: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
17. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ: Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856- 1862.
18. Manns MP, von Hahn T: Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610.
19. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, et al: Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-849; quiz e12.
20. Rehermann B, Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229.
21. Arzumanyan A, Reis HMGPV, Feitelson MA: Pathogenic mechanisms in HBV- and HCVassociated hepatocellular carcinoma. Nat Rev 2013; 13: 123-135.
22. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV, et al: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
23. Akbar SMF, Inaba K, Onji M: Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon- ? abrogation of immune response defect to a T-cell-dependent antigen. Immunology 1996; 87: 519-527.
24. Chow WC Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, Degos F, et al: Re-treatment with interferon-? of patients with chronic hepatitis C. Hepatology 1998; 27: 1144-1148.
25. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646- 674.
26. Pan J, Lian Z, Wallett S, Feitelson MA: The hepatitis B X antigen effector, URG7, blocks tumour necrosis factor ?-mediated apoptosis by activation of phosphoinositol 3-kinase and ?-catenin. J Gen Virol 2007; 88: 3275-3285.
27. Jin Y, Fuller L, Carreno M, Zucker K, Roth D, Esquenazi V, Karatzas T, et al: The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage. J Clin Immunol 1997; 17: 140-153.
28. Bhargava A, Raghuram GV, Pathak N, Varshney S, Jatawa SK, Jain D, Mishra PK: Occult hepatitis C virus elicits mitochondrial oxidative stress in lymphocytes and triggers PI3- kinase-mediated DNA damage response. Free Radic Biol 2011; 51: 1806-1814.
29. Cho HK, Cheong KJ, Kim HY, Cheong J: Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclo-oxygenase 2 expression via activating transcription factor 4. Biochem J 2011; 435: 431-439.
30. Clippinger AJ, Bouchard MJ: Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. J Virol 2008; 82: 6798-6811.
31. Yang B, Bouchard MJ: The hepatitis B virus X protein elevates cytosolic calcium signals by modulating mitochondrial calcium uptake. J Virol 2012; 86: 313-327.
32. Bouchard MJ, Puro RJ, Wang L, Schneider RJ: Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol 2003; 77: 7713-7719.
33. Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, Koike K: Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology 2011; 81:S11-S17.
34. Balsano C, Avantaggiati ML, Natoli G, De Marzio E, Will H, Perricaudet M, Levrero M: Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun 1991; 176: 985-992.
35. Wu CG, Salvay DM, Forgues M, Valerie K, Farnsworth J, Markin RS, Wang XW: Distinctive gene expression profiles associated with hepatitis B virus X protein. Oncogene 2001; 20: 3674-3682.
36. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, Pischon T, et al: Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested casecontrol study. J Natl Cancer Inst 2011; 103: 1686-1695.
37. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
38. Chuang SC, Lee YCA, Hashibe M, Dai M, Zheng Tand Boffetta P: Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev 2010; 19: 1261-1268.
39. Seitz HK, Stickel F: Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387: 349-360.
40. Seitz HK, Wang XD: The role of cytochrome P450 2E1 in ethanol-mediated carcinogenesis. Subcell Biochem 2013; 67: 131-143.
41. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, et al: Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007; 46: 430-435.
42. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C: Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1413-1421.
43. Muriel P, Arauz J: Coffee and liver diseases. Fitoterapia 2010; 81: 297-305.
44. McGlynn KA, London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 3-23.
45. Wu HC, Santella R: The role of aflatoxins in hepatocellular carcinoma. Hepat Mon 2012; 12:e7238.
46. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, et al: p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471-3477.
47. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al: Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30: 379-383.
48. Lazo M, Clark JM: The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
49. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, et al: Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012; 55: 1416- 1425.
50. Rafiq N, Bai C, Fang Y, Srishord M, Mc- Cullough A, Gramlich T, Younossi ZM: Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
51. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625- 1638.
52. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999- 2004. JAMA 2006; 295: 1549-1555.
53. Haslam DW, James WPT: Obesity. Lancet 2005; 366: 1197-1209.
54. Larsson SC, Wolk A: Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008.
55. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, et al: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443.
56. Petta S, Craxi A: Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. Curr Pharm Des 2010; 16: 741-752.
57. Pietrangelo A: Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J Hepatol 2009; 50: 249-251.
58. Pietrangelo A: Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82: 1142-1146.
59. Duan XY, Zhang L, Fan JG, Qiao L: NAFLD leads to liver cancer: Do we have sufficient evidence? Canc Lett 2013, Epub ahead of print.
60. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W: Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-891.
61. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, et al: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615.
62. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA: Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013; 24: 469-480.
63. Pietrangelo A: Hereditary hemochromatosis - a new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
64. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 62: 1907-1917.
65. Scott CR: The genetic tyrosinemias. Am J Med Genet C Semin Med Genet 2006; 142C:121-126.
66. Weinberg AG, Mize CE, Worthen HG: The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976; 88: 434-438.
67. Holme E, Lindstedt S: Tyrosinemia type 1 and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)- 1,3-cyclohexanedione). J Inherit Metab Dis 1998; 21: 507-517.
68. Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al: NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008; 31: 81-87.
69. Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS, Shen XZ, et al: Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol 2011; 137: 1095-1104.
70. Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
71. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
72. Woo HG, Park ES, Thorgeirsson SS, Kim YJ: Exploring genomic profiles of hepatocellular carcinoma. Mol Carcinog 2011; 50: 235-243.
73. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.
74. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
75. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T: A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013; 145: 176-187.
76. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hue C, Andersson KL, Chung RT, et al: Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144: 1024-1030.
77. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, et al: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694-698.
78. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, et al: Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 2013; 58: 1693-1702.